Welcome to our dedicated page for Predictive Oncology news (Ticker: POAI), a resource for investors and traders seeking the latest updates and insights on Predictive Oncology stock.
Predictive Oncology Inc. (NASDAQ: POAI), which is changing its corporate name to Axe Compute Inc. with an expected ticker transition to AGPU, generates news at the intersection of AI‑driven oncology, capital markets activity, and digital asset‑enabled AI infrastructure. Company announcements emphasize its use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for cancer patients, as well as its newer digital asset treasury strategy focused on ATH, the native utility token of the Aethir network.
News updates frequently cover financial results and corporate updates, including quarterly earnings releases, shareholder letters, and discussions of operating performance. These communications often describe progress in validating proprietary technologies, such as the PEDAL AI platform and the ChemoFx live‑cell tumor profiling assay, along with efforts to expand the availability of ChemoFx in the United States and prepare for a de novo launch in Europe.
Investors following POAI can also expect transaction and financing news, such as private placements involving cash and digital assets, reverse stock split announcements, at‑the‑market offering updates, and standby equity purchase agreements. Recent disclosures describe substantial private investment in support of the company’s digital asset treasury strategy, as well as Nasdaq compliance updates related to stockholders’ equity and bid price requirements.
Another recurring theme in the news flow is strategic partnerships and governance developments. Examples include the strategic collaboration with Every Cure on drug repurposing, collaborations related to 3D liver toxicity models, and appointments of new board members and senior leaders to support the digital asset treasury and AI initiatives. Updates on the evolution of the company’s business model, including the creation of a Strategic Compute Reserve through ATH holdings on the Aethir ecosystem, are also highlighted.
For readers and investors, the POAI news page provides a consolidated view of these developments, allowing closer tracking of the company’s oncology‑focused AI activities, its digital asset strategy, and key regulatory and listing milestones.
Predictive Oncology (POAI) reported its Q3 2020 financial results, maintaining revenues at $0.5 million, similar to the previous year. The company achieved a gross margin of 64%, up from 60%, attributed to reduced manufacturing costs. However, operating loss rose to $5.6 million, influenced by a $3.0 million non-cash goodwill impairment. The net loss increased to $6.9 million, or $(0.46) per share, compared to $(1.31) per share in 2019. Business highlights included signing a contract with a pharmaceutical company and licensing 71 unique ovarian cancer cell lines, bringing the total to 96.
Predictive Oncology (NASDAQ: POAI) CEO Carl Schwartz discussed the company's recent milestones and future goals in an interview with NetworkNewsWire. Key subsidiaries highlighted include TumorGenesis, which has developed a novel lab media to replace animal testing for tumors, and Soluble Biotech, which has expanded its research capabilities. Schwartz also emphasized Helomics' extensive tumor data, which positions it for competitive success in the market. The full interview provides further insights into these developments and the company's strategic direction.
Predictive Oncology (NASDAQ: POAI) released a letter from CEO Carl Schwartz addressing shareholders amid a declining stock price. Despite this downturn, he assures investors of positive progress, highlighting stable cash burn and increasing revenue trends. The company’s divisions, including Skyline Medical and Helomics, are experiencing operational advancements, with new product launches and successful collaborations. Predictive Oncology is poised for growth, with solid cash reserves and strategic partnerships on the horizon, aiming for revenue generation by year-end.
TumorGenesis, a division of Predictive Oncology (NASDAQ: POAI), has acquired a license for 71 unique ovarian cancer cell lines, increasing its total to 96. This was done in collaboration with Ximbio, enhancing research capabilities in ovarian cancer. The new media developed for these cells retains over 95% of DNA and RNA, providing a robust tool for researchers. Richard Gabriel, President of TumorGenesis, emphasized that this advancement addresses the challenges presented by standard media mixes and aims to improve reproducibility in preclinical research, potentially saving the industry billions in research costs.
Predictive Oncology (NASDAQ: POAI) announced its participation in the LD Micro's LD 500 Virtual Investor Conference, scheduled for September 2, 2020, at 3:40 PM ET. The event will provide an opportunity for company management to present and discuss its advancements in artificial intelligence applied to personalized medicine and drug discovery. A live webcast will be available to the public and archived for 90 days. For more details, visit the webcast link.
Predictive Oncology (NASDAQ: POAI) announced the sale of 8 STREAMWAY systems to a Virginia university hospital for a new surgical center, adding to the 2 systems already in use. This transaction is anticipated to yield approximately 4,000 procedures annually. In total, the company has sold 13 STREAMWAY systems in Q3 2020. The STREAMWAY System automates medical fluid disposal, showcasing POAI's advancements in personalized medicine and AI application in drug discovery.
Predictive Oncology (NASDAQ: POAI) announces that its chief innovation officer, Mark Collins, Ph.D., recently spoke on DojoLIVE!, discussing the potential of AI in cancer treatment. Helomics, a subsidiary, utilizes its Tumor Drug Response Profiling (TDRP) platform, which has generated profiles from over 150,000 tumors, aiming to personalize cancer therapies and collaborate with pharma on new therapies. The company also operates TumorGenesis and Skyline Medical. It's important to note the inherent risks in forward-looking statements as they may vary from actual results.
Predictive Oncology (NASDAQ: POAI) reported Q2 2020 financial results, highlighting a revenue of $183,000, down from $286,000 year-over-year. The company achieved its first commercial sale of ovarian cancer cell media and completed acquisitions of Soluble Therapeutics and BioDtech, enhancing its capabilities in precision medicine. The net loss was $3.6 million, with improvements in operational expenses. Management is optimistic about ongoing Helomics and TumorGenesis initiatives while raising $4.6 million through equity offerings to strengthen liquidity.
Predictive Oncology (NASDAQ: POAI) released a letter to shareholders highlighting key business achievements and proposals for a vote on September 3, 2020. Significant accomplishments include the acquisition of Quantitative Medicine, enhancing AI-driven drug discovery, and the first commercial sale of ovarian cancer media. The company also aims to reprice stock options and increase its share reserve to attract talent. Recent financial improvements encompass a $4.4 million capital raise and restructuring of debt, aimed at positioning the company for future growth and enhancing shareholder value.
Predictive Oncology (NASDAQ: POAI) has acquired Quantitative Medicine LLC in an all-stock deal valued at approximately $1.8 million. This acquisition integrates QM's CoRE™ drug discovery platform, aimed at enhancing Predictive Oncology's capabilities in personalized medicine and drug development. Leveraging a database from over 150,000 cancer cases, the combined efforts are expected to accelerate the development of new anti-cancer therapeutics and improve patient outcomes. The acquisition is also anticipated to generate revenue from future pharmaceutical collaborations.
FAQ
What is the current stock price of Predictive Oncology (POAI)?
What is the market cap of Predictive Oncology (POAI)?
